Progress And Opportunities In Asian Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
The incidence of the five main types of cancer in Asia is expected to surge and multinational and non-industry sponsors alike are increasing the number of clinical trials they conduct in the region, particularly of targeted drugs. A new analysis identifies major trends and opportunities.